Study guide

3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology

Board Certified Specialist in Renal Nutrition CSR

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Kidney Disease Foundations

1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk

2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment

2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry

3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools

3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss

4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History

4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment

5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality

5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment

6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning

6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances

7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients

7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy

8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy

8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)

9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients

9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD

10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support

10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support

11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities

11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure

12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends

12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories

13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics

13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence

14 Chapter 14: Domain 2 — Care Coordination, Communication & Education

14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support

15 Chapter 15: Domain 3 — Regulations & Quality Management

15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool

16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols

16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways

3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology

Key Takeaways Explain This Topic AI

The International Society of Renal Nutrition and Metabolism (ISRNM) consensus diagnostic criteria for Protein-Energy Wasting (PEW) require meeting at least one objective criterion across at least three of four categories: serum chemistry, body mass, muscle mass, and dietary intake.

The ISRNM albumin criterion for PEW is below 3.8 g/dL by bromocresol green; bromocresol purple reads lower, so BCP results are judged against the lab's own range.

Metabolic acidosis (serum bicarbonate <22 mEq/L) triggers skeletal muscle proteolysis by activating caspase-3 to cleave complex actomyosin complexes, releasing 14-kDa actin fragments for accelerated degradation by the ATP-dependent ubiquitin-proteasome system (UPS).

The reverse epidemiology or obesity paradox in maintenance hemodialysis demonstrates that overweight and mildly obese states (BMI 25–34.9 kg/m²) confer protective survival advantages against all-cause and cardiovascular mortality compared to normal or low body mass index.

Obligatory dialytic nutrient clearance accounts for significant daily protein and amino acid deficits, with hemodialysis removing 6–12 g of free amino acids per session and peritoneal dialysis losing 5–15 g of protein alongside 2–4 g of amino acids daily.

Last updated: September 2026

Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology

Core Clinical Principle: Protein-Energy Wasting (PEW) is a state of systemic nutritional and metabolic exhaustion unique to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Unlike simple non-renal starvation, which is reversed by caloric supplementation, PEW is driven by accelerated muscle proteolysis, chronic microinflammation, and profound neuroendocrine derangements that resist conventional refeeding unless the underlying uremic and inflammatory drivers are concurrently managed.

In 2008, the International Society of Renal Nutrition and Metabolism (ISRNM) formally introduced the diagnostic term Protein-Energy Wasting (PEW) to replace ambiguous and inconsistent terms such as "uremic malnutrition," "renal cachexia," and "malnutrition-inflammation complex syndrome." PEW defines a pathological state characterized by the concurrent, progressive depletion of both somatic skeletal muscle stores and visceral protein/energy compartments in patients with kidney disease.

1. ISRNM Consensus Diagnostic Criteria for PEW

To establish an evidence-based, clinically reproducible diagnosis of PEW, the ISRNM expert panel established four distinct diagnostic categories. A confirmed diagnosis of PEW requires that a patient satisfy at least one objective criterion in at least three of the four categories .

The Four Diagnostic Categories and Clinical Thresholds

Diagnostic Category Objective Clinical Parameters Validated Diagnostic Thresholds

1. Serum Chemistry • Serum Albumin; Serum Prealbumin (Transthyretin); Serum Total Cholesterol • Albumin < 3.8 g/dL by bromocresol green (BCG); Prealbumin < 30 mg/dL (maintenance dialysis only); Total Cholesterol < 100 mg/dL (not valid when low because of urinary or GI protein losses, liver disease or cholesterol-lowering drugs)

2. Body Mass • Body Mass Index (BMI); Unintentional Weight Loss; Total Body Fat Percentage • BMI < 23 kg/m² (a lower cutoff may suit some Asian populations); Unintentional weight loss > 5% over 3 months OR > 10% over 6 months ; Total body fat < 10%

3. Muscle Mass • Skeletal Muscle Mass Loss; Mid-Arm Muscle Circumference (MAMC); Sarcopenia / Muscle Wasting • Muscle mass reduction > 5% over 3 months OR > 10% over 6 months ; MAMC reduction > 10% relative to the 50th percentile of the reference population

4. Dietary Intake • Normalized Protein Intake (nPCR / nPNA); Dietary Energy Intake (DEI) • Unintentional low dietary protein intake < 0.80 g/kg/day for at least 2 months on dialysis ( < 0.6 g/kg/day in CKD stages 2–5); Low dietary energy intake < 25 kcal/kg/day for at least 2 months

Analytical Nuance: Bromocresol Green (BCG) vs. Bromocresol Purple (BCP)

A critical competency for the Board Certified Specialist in Renal Nutrition (CSR) is recognizing laboratory assay methodology when interpreting serum albumin:

Bromocresol Green (BCG): Overestimates serum albumin by approximately 0.2 to 0.4 g/dL because BCG non-specifically binds to acute-phase alpha-1 and alpha-2 globulins, fibrinogen, and ferritin. In inflamed ESRD patients with high circulating acute-phase proteins, BCG yields an artificially elevated albumin reading. The ISRNM albumin criterion ( < 3.8 g/dL ) is specified for the BCG method.

Bromocresol Purple (BCP): More specific for albumin, so it reads lower than BCG in the same sample, often by several tenths of a g/dL in dialysis patients. The ISRNM cutoff was written for BCG; when your lab uses BCP, judge albumin against the lab's own range (the CMS survey tool also uses the lab's normal range for BCP).

2. Molecular Pathophysiology of PEW

PEW does not stem from simple voluntary dietary restriction; it is an active hypercatabolic syndrome mediated by converging molecular pathways: +-------------------------------------------------------------+

  • | Uremic Toxicity |
  • | (Indoxyl Sulfate, p-Cresyl Sulfate, Guanidino Compounds) |
  • +------------------------------+------------------------------+
  • |
  • v
  • +-------------------------------------------------------------+
  • | Chronic Microinflammation (MICS) |
  • | (Elevated IL-1, IL-6, TNF-alpha, hs-CRP) |
  • +------------------------------+------------------------------+
  • |
  • +------------------------+------------------------+
  • | |
  • v v
  • +-------------------------------+ +-------------------------------+
  • | Metabolic Acidosis | | Hypothalamic Appetite |
  • | (Serum HCO3 < 22 mEq/L) | | Dysregulation |
  • | | | (Leptin Resistance, Low NPY) |
  • | • Cleavage of Actomyosin by | | |
  • | Caspase-3 | | • Uremic Dysgeusia |
  • | • Ubiquitination via E3 | | • Severe Uremic Anorexia |
  • | Ligases (MuRF-1, Atrogin-1)| | • Inadequate Caloric Intake |
  • | • 26S Proteasome Proteolysis | +---------------+---------------+
  • | • BCKAD Oxidation of BCAAs | |
  • +---------------+---------------+ |
  • | |
  • v v
  • +---------------------------------------------------------------------------------+
  • | Protein-Energy Wasting (PEW) |
  • | • Progressive Muscle Wasting • Visceral Hypoalbuminemia |
  • | • Loss of Adipose Stores • High Cardiovascular Mortality |
  • +---------------------------------------------------------------------------------+
  • A. Uremic Toxins and the Gut-Kidney Axis

Progressive nephron loss results in systemic accumulation of gut-derived, protein-bound uremic retention solutes, notably indoxyl sulfate (derived from dietary tryptophan metabolism) and p-cresyl sulfate (derived from dietary tyrosine and phenylalanine metabolism). These toxins accumulate intracellularly via organic anion transporters (OAT1/OAT3), inducing high levels of reactive oxygen species (ROS), mitochondrial uncoupling, and cellular senescence in skeletal myocytes. Uremic toxins blunt protein synthesis by downregulating the mammalian target of rapamycin (mTOR) signaling cascade.

B. Systemic Microinflammation and Cytokine Cascades

Patients on maintenance dialysis experience continuous low-grade systemic inflammation (hs-CRP > 3.0 mg/L) driven by dialyzer membrane bioincompatibility, endotoxin translocation across a degraded intestinal epithelial barrier, periodontal disease, and thrombosed vascular access grafts. Pro-inflammatory cytokines—predominantly Interleukin-6 (IL-6) , Tumor Necrosis Factor-alpha (TNF-α) , and Interleukin-1 (IL-1) —bind to myocyte membrane receptors, activating the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcription factor.

Simultaneously, IL-6 directly reprograms hepatic protein synthesis: it upregulates positive acute-phase reactants (CRP, ferritin, fibrinogen) while downregulating the gene transcription of negative acute-phase proteins ( albumin , prealbumin , and transferrin ). Consequently, hypoalbuminemia in ESRD reflects systemic inflammation as much as it does nutritional depletion.

C. Metabolic Acidosis and the Ubiquitin-Proteasome System (UPS)

Metabolic acidosis (serum bicarbonate < 22 mEq/L) is one of the most potent triggers of accelerated muscle breakdown in renal disease. Skeletal muscle protein catabolism by acidosis occurs through a defined, two-step enzymatic pathway:

Initial Actomyosin Cleavage via Caspase-3: Intact myofibrillar proteins (actin and myosin) are physically too large and structured to fit directly into the proteolytic core of the proteasome. Metabolic acidosis and elevated glucocorticoids stimulate active caspase-3 , which cleaves complex actomyosin into individual, degraded 14-kDa actin fragments.

The ATP-Dependent 26S Ubiquitin-Proteasome System (UPS): These 14-kDa actin fragments are marked for destruction by muscle-specific E3 ubiquitin ligases—specifically Muscle RING-Finger Protein 1 (MuRF-1) and Atrogin-1 (MAFbx) . Polyubiquitin chains are enzymatically tethered to the substrate, and the marked proteins are threaded into the 26S proteasome core, where they undergo rapid proteolysis into oligopeptides and free amino acids.

Branched-Chain Amino Acid Oxidation: Chronic acidosis markedly stimulates the activity of branched-chain alpha-ketoacid dehydrogenase (BCKAD) in skeletal muscle, dramatically increasing the irreversible decarboxylation and oxidation of essential branched-chain amino acids (leucine, isoleucine, and valine), rapidly depleting systemic somatic protein reserves.

D. Endocrine Derangements and Hypothalamic Appetite Suppression

Insulin and IGF-1 Resistance: Uremia impairs post-receptor insulin signaling in skeletal muscle, specifically inhibiting the Phosphoinositide 3-kinase (PI3K) / protein kinase B (Akt) pathway. This dampens protein synthesis while removing the inhibitory brake on FoxO transcription factors, further upregulating Atrogin-1 and MuRF-1.

Secondary Hyperparathyroidism (SHPT): Severely elevated intact Parathyroid Hormone (iPTH) increases intracellular calcium influx in myocytes, accelerating muscle proteolysis and uncoupling mitochondrial oxidative phosphorylation, which increases resting energy expenditure (REE).

Central Leptin Resistance and Anorexia: Leptin, an adipokine cleared by renal tubular catabolism, accumulates 3- to 5-fold in ESRD. Circulating hyperleptinemia fails to be balanced by central feedback due to hypothalamic leptin resistance. Central melanocortin signaling becomes deranged: pro-opiomelanocortin (POMC) neurons are persistently stimulated, while orexigenic neuropeptide Y (NPY) neurons are downregulated, driving severe, intractable uremic anorexia and dysgeusia.

E. Obligatory Dialytic Nutrient Losses

Dialysis therapy itself is an obligatory catabolic event. During standard high-flux hemodialysis, 6 to 12 grams of free amino acids are filtered across the dialyzer membrane into the waste stream per treatment. In peritoneal dialysis, dialytic effluent drains 5 to 15 grams of intact protein (primarily albumin) and 2 to 4 grams of amino acids per 24-hour dwell period . During acute episodes of peritonitis, peritoneal membrane pore dilation and severe mesothelial inflammation can escalate daily peritoneal protein losses to > 20 to 30 grams per day , rapidly plunging the patient into acute, decompensated PEW.

3. Reverse Epidemiology: The Dialysis Obesity Paradox

In the general population, an elevated Body Mass Index (BMI ≥ 25–30 kg/m²) is strongly correlated with increased cardiovascular disease and all-cause mortality. In sharp contrast, large-scale nephrology registry data (e.g., DOPPS, USRDS) consistently demonstrate an obesity paradox or reverse epidemiology among maintenance hemodialysis patients: overweight (BMI 25–29.9 kg/m²) and Class I obese (BMI 30–34.9 kg/m²) patients exhibit the lowest all-cause and cardiovascular mortality rates , whereas patients with normal (BMI 18.5–22.9 kg/m²) or underweight (BMI < 18.5 kg/m²) status experience dramatically elevated mortality.

Proposed Pathophysiological Mechanisms

Nutritional Buffering Against Acute Catabolic Stress: Dialysis patients face recurrent catabolic shocks from vascular access sepsis, fluid overload hospitalizations, and cardiovascular events. Greater somatic adipose and muscle reserves provide critical energetic and nitrogenous substrate, preventing fatal tissue exhaustion.

Lipophilic Uremic Toxin and Cytokine Sequestration: Adipose tissue serves as a passive repository capable of sequestering lipophilic uremic retention molecules and toxic xenobiotics away from vital vascular endothelium and myocardial tissue. Adipocytes also secrete soluble TNF receptors (sTNF-R1 and sTNF-R2), which bind and neutralize circulating bioactive TNF-α.

Hemodynamic Stability: Dialysis patients with higher body weight and larger circulating plasma volumes experience fewer episodes of symptomatic intradialytic hypotension (IDH). Mitigating IDH prevents transient subclinical myocardial stunning and mesenteric ischemia, preserving residual renal function and cardiac output.

Important Clinical Caveat — Sarcopenic Obesity: While high BMI is epidemiologically protective, renal dietitians must differentiate between muscular mass and sarcopenic obesity. In sarcopenic obesity, patients possess excessive adipose tissue alongside severe skeletal muscle wasting. Sarcopenic obesity does not confer the same protective advantage as true somatic muscular bulk, and it presents high risks of physical disability and metabolic dysregulation.

Loading diagram... Molecular Pathophysiology of Protein-Energy Wasting